paxalisib (GDC-0084)

News alerts, weekly reports and conference planners

Company:

Kazia, Roche, Simcere, SoVarGen

Drug class:

mTOR inhibitor, PI3K inhibitor, AKT inhibitor

No biomarker	Glioblastoma	No biomarker	Glioblastoma	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
BRAF mutation	Melanoma	BRAF mutation	Melanoma	GDC-0084 Sensitive: D – Preclinical GDC-0084 Sensitive : D	GDC-0084 Sensitive: D – Preclinical GDC-0084 Sensitive : D

Associations
(3)